SWX:POLN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Polyphor AG, a clinical stage biopharmaceutical company, focuses on developing macrocycle drugs for cancer. More Details


Snowflake Analysis

Flawless balance sheet with high growth potential.

Share Price & News

How has Polyphor's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: POLN is more volatile than 75% of Swiss stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: POLN's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of Swiss stocks.


Market Performance


7 Day Return

-1.8%

POLN

3.6%

CH Biotechs

0.4%

CH Market


1 Year Return

7.4%

POLN

1.3%

CH Biotechs

-0.4%

CH Market

Return vs Industry: POLN exceeded the Swiss Biotechs industry which returned 1.3% over the past year.

Return vs Market: POLN exceeded the Swiss Market which returned -0.4% over the past year.


Shareholder returns

POLNIndustryMarket
7 Day-1.8%3.6%0.4%
30 Day-1.2%1.5%2.8%
90 Day-10.3%2.0%5.8%
1 Year7.4%7.4%2.6%1.3%3.1%-0.4%
3 Yearn/a4.3%1.9%19.8%4.7%
5 Yearn/a71.8%66.0%51.9%26.8%

Long-Term Price Volatility Vs. Market

How volatile is Polyphor's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Polyphor undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: POLN (CHF8) is trading below our estimate of fair value (CHF252.13)

Significantly Below Fair Value: POLN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: POLN is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.

PE vs Market: POLN is unprofitable, so we can't compare its PE Ratio to the Swiss market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate POLN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: POLN's PB Ratio (3x) is in line with the CH Biotechs industry average.


Next Steps

Future Growth

How is Polyphor forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

60.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: POLN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.3%).

Earnings vs Market: POLN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: POLN's is expected to become profitable in the next 3 years.

Revenue vs Market: POLN's revenue (43.3% per year) is forecast to grow faster than the Swiss market (4.6% per year).

High Growth Revenue: POLN's revenue (43.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: POLN is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Polyphor performed over the past 5 years?

-19.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: POLN is currently unprofitable.

Growing Profit Margin: POLN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: POLN is unprofitable, and losses have increased over the past 5 years at a rate of 19.6% per year.

Accelerating Growth: Unable to compare POLN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: POLN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.3%).


Return on Equity

High ROE: POLN has a negative Return on Equity (-218.38%), as it is currently unprofitable.


Next Steps

Financial Health

How is Polyphor's financial position?


Financial Position Analysis

Short Term Liabilities: POLN's short term assets (CHF47.2M) exceed its short term liabilities (CHF13.4M).

Long Term Liabilities: POLN's short term assets (CHF47.2M) exceed its long term liabilities (CHF14.7M).


Debt to Equity History and Analysis

Debt Level: POLN's debt to equity ratio (7.5%) is considered satisfactory.

Reducing Debt: POLN's debt to equity ratio has reduced from 8.9% to 7.5% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: POLN has sufficient cash runway for 10 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: POLN is forecast to have sufficient cash runway for 11 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Polyphor current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate POLN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate POLN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if POLN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if POLN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of POLN's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.6yrs

Average management tenure


CEO

Gokhan Batur (38 yo)

1

Tenure

Mr. Gokhan Batur has been the Chief Executive Officer at Polyphor AG since January 23, 2020 and had been its Chief Commercial Officer since June 3, 2019 until January 23, 2020. Mr. Batur joined Polyphor in...


Leadership Team

NamePositionTenureCompensationOwnership
Gokhan Batur
Chief Executive Officer1yrno datano data
Daniel Obrecht
Co-Founder & Chief Scientific Officer25yrsno data1.74%
CHF 1.6m
Hernan Levett
Chief Financial Officer1.25yrsno datano data
Franziska Müller
Head of Human Resourcesno datano data0.012%
CHF 11.2k
Frank Weber
Chief Medical & Development Officer2yrsno datano data

1.6yrs

Average Tenure

45yo

Average Age

Experienced Management: POLN's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Kuno Sommer
Chairman1.17yrsno data0.045%
CHF 40.0k
Silvio Inderbitzin
Director4.58yrsno data0.16%
CHF 142.0k
Bernard Bollag
Director7.58yrsno data0.047%
CHF 41.9k
Andreas Wallnöfer
Vice Chairman1.17yrsno datano data

2.9yrs

Average Tenure

59yo

Average Age

Experienced Board: POLN's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Polyphor AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Polyphor AG
  • Ticker: POLN
  • Exchange: SWX
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CHF89.667m
  • Shares outstanding: 11.21m
  • Website: https://www.polyphor.com

Number of Employees


Location

  • Polyphor AG
  • Hegenheimermattweg 125
  • Allschwil
  • Basel-Landschaft
  • 4123
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
POLNSWX (SIX Swiss Exchange)YesCommon SharesCHCHFMay 2018
29YDB (Deutsche Boerse AG)YesCommon SharesDEEURMay 2018

Biography

Polyphor AG, a clinical stage biopharmaceutical company, focuses on developing macrocycle drugs for cancer. Its lead drug candidates include Balixafortide (POL6326), an antagonist of the chemokine receptor...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/16 18:12
End of Day Share Price2021/01/15 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.